Home Transmembrane Transporters Calcium Channel chemical Levosimendan For research use only.

Levosimendan

Synonyms: OR1259,OR1855,Simsndan

Levosimendan(OR1259,OR1855,Simsndan) is a calcium sensitizer acting through calcium-dependent binding to cardiac troponin C (cTnC), provides treatment for heart failure.

Levosimendan Chemical Structure

Levosimendan Chemical Structure

CAS: 141505-33-1

Selleck's Levosimendan has been cited by 1 Publication

1 Customer Review

Purity & Quality Control

Batch: Purity: 99.95%
99.95

Other Calcium Channel Products

Related compound libraries

Choose Selective Calcium Channel Inhibitors

Biological Activity

Description Levosimendan(OR1259,OR1855,Simsndan) is a calcium sensitizer acting through calcium-dependent binding to cardiac troponin C (cTnC), provides treatment for heart failure.
Targets
Cardiac troponin C [1]
In vitro
In vitro

Levosimendan is a calcium sensitizer acting through calcium-dependent binding to cardiac troponin C (cTnC). Levosimendan at 3 μM decreases the value of Ca50 from 2.73μM to 1.19 μM. levosimendan exhibits its calcium sensitizing effect through calcium-dependent binding to the N-terminal domain of cTnC. [1] Levosimendan significantly hyperpolarizes resting potential of rat mesenteric arterial myocytes with an EC50 of 2.9 μM and maximal effect (19.5 mV) at 10 μM, probably through activation of a glibenclamide-sensitive K+ channel. [2] Levosimendan has inotropic and lusitropic actions in failing human myocardium, with average maximum increase in twitch tension of 47% at a levosimendan concentration of 0.8 μM. [3] Levosimendan causes rapid dose-dependent improvement in hemodynamic function in patients with decompensated heart failure. [4]
In Vivo
In vivo

Levosimendan at low concentrations (0.03 to 0.1 μM) acts preferably as a Ca2+ sensitizer, whereas at higher concentrations (0.1 to 0.3 μmol/L) its action as a phosphodiesterase inhibitor contributes to the positive inotropic effect. [5]
Animal Research Animal Models guinea pig heart
Dosages 0.03, 0.1, 0.3 μM
Administration administered into the buffer flow line
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04705337 Not yet recruiting Heart Failure New York Heart Association Class III|Heart Failure New York Heart Association Class IV|Heart Failure Systolic|Heart Failure With Reduced Ejection Fraction Medical University of Bialystok|Medical Research Agency Poland|University of Opole|Medical University of Lodz|Poznan University of Medical Sciences|Nicolaus Copernicus University|National Institute of Cardiology Warsaw Poland|John Paul II Hospital Krakow|Azienda Ospedaliera dei Colli January 1 2021 Phase 4
NCT04252404 Completed Acute Heart Failure Arcothova February 3 2020 --
NCT05076864 Recruiting Pharmacokinetics|Metabolites|Intensive Care|Renal Failure|Acute Kidney Injury Karolinska Institutet|Karolinska University Hospital January 1 2020 --
NCT04323709 Completed Cardiogenic Shock|Refractory Shock Hospices Civils de Lyon January 1 2019 --
NCT03681379 Unknown status Acute Heart Failure Nantes University Hospital October 1 2018 --
NCT03764722 Unknown status Systolic Heart Failure Collegium Medicum w Bydgoszczy August 1 2018 Phase 4

Chemical lnformation & Solubility

Molecular Weight 280.28 Formula

C14H12N6O
CAS No. 141505-33-1 SDF Download Levosimendan SDF
Smiles CC1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 56 mg/mL ( (199.8 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Levosimendan | Levosimendan ic50 | Levosimendan price | Levosimendan cost | Levosimendan solubility dmso | Levosimendan purchase | Levosimendan manufacturer | Levosimendan research buy | Levosimendan order | Levosimendan mouse | Levosimendan chemical structure | Levosimendan mw | Levosimendan molecular weight | Levosimendan datasheet | Levosimendan supplier | Levosimendan in vitro | Levosimendan cell line | Levosimendan concentration | Levosimendan nmr